Viewing nowCombinationOldip Tablet 10/40 Milligrams
Amlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Ilhwa Co., Ltd.

MFDS item code 201404995 · Approved 2014.10.28 · Insurance code 640902830
Treatment of essential hypertension not controlled with monotherapy
Amlodipine or Olmesartan Medoxomil is used for patients with essential hypertension who have difficulty controlling blood pressure. These medications relax blood vessels and lower blood pressure. It is used as a treatment when blood pressure control is insufficient with monotherapy. Regular use can stabilize blood pressure and help reduce the risk of complications from hypertension. Therefore, it is effectively used in the treatment of essential hypertension.
Take 1 tablet once daily with water, with or without food. It is recommended, if possible, to take this medicine at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose of each individual component (amlodipine or olmesartan medoxomil) be adjusted. However, if blood pressure is not controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows: - 5/20 milligrams: For patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: For patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 milligrams once daily. Administration of this medicine is not recommended for patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended for patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: For patients who may have reduced effective intravascular volume (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil for patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. Blood pressure and renal function should be closely monitored in patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics. This medicine must not be administered to patients with severe hepatic impairment. (See section 2, Patients who must not be administered this medicine, under Precautions for Use.) ∘Older adults: In general, initiate treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbidities. Blood pressure should be monitored closely and more frequently in older adults.
Safety and efficacy have not been established in pediatric patients under 18 years of age.
This medication can cause serious harm or death to the fetus and newborn during the second and third trimesters of pregnancy, so it should be stopped immediately upon confirmation of pregnancy. Patients with allergy to any of the main ingredients or similar drug classes, women who are pregnant or breastfeeding, patients with severely impaired liver or kidney function, and those with certain heart diseases should not take this medication. Patients with insufficient water or salt levels may experience hypotension, so their condition should be monitored closely during the initial dosage, and appropriate measures should be taken if hypotension occurs. Although rare, there may be instances of sudden vasodilation leading to hypotension, so special care should be taken in patients with heart valve diseases. Patients with cardiovascular diseases or heart failure may experience worsening symptoms with this medication, and should take it cautiously under the guidance of a physician. Patients with compromised kidney function are at higher risk for further kidney impairment while taking this medication, so regular monitoring is necessary. Patients with liver dysfunction may experience delayed metabolism of this medication, requiring careful attention during use. During treatment with this medication, side effects such as dizziness, headache, hypotension, digestive disorders, rash, and edema may occur, and patients should consult a doctor if symptoms are severe or persistent. Taking this medication while pregnant may pose a risk to the fetus, so those planning to become pregnant or who are already pregnant should consult their physician. Breastfeeding may pass this medication into breast milk and affect the baby, so mothers should consult their physician on whether to continue or stop breastfeeding. The safety and efficacy of this medication have not been established for children under 18 years of age, and it is not recommended. Elderly patients should exercise extra caution due to decreases in liver, kidney, and heart function, and it is generally advisable to start with a lower dosage. In case of overdose, severe hypotension and vascular dilation may occur, and if symptoms arise, immediate hospital treatment is necessary. This medication should be stored in a tightly closed container, away from moisture, heat, and direct sunlight, out of the reach of children.
Not everyone experiences these, and they can vary from person to person.
This medication is susceptible to air and moisture, so it should be stored in a tightly closed container. Additionally, it is safest to store it at room temperature between 1°C and 30°C, avoiding excessively hot or cold places.
Brownish-red round film-coated tablet
28 tablets/box [(14 tablets/PTP x2)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Ilhwa Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.